Open AccessColchicine (Myinfla)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.311
Subject(s) - reimbursement , antithrombotic , medicine , drug , drug class , colchicine , intensive care medicine , family medicine , pharmacology , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses colchicine (Myinfla), 0.5 mg extended-release oral tablet.
Indication: For the reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including low-density lipoprotein cholesterol (LDL-C)–lowering and antithrombotic drug treatment.